FDA Adds Heart Failure Warning To Saxagliptin and Alogliptin Labels
The FDA said on Tuesday that it was adding new warning to the labels of diabetes drugs containing the saxagliptin and alogliptin. The FDA said the drugs “may increase the risk of heart failure, particularly in patients who already have heart or kidney disease.” The announcement comes two years after an FDA panel recommended that...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Larry Husten Tags: Diabetes Heart Failure Policy & Ethics Prevention, Epidemiology & Outcomes Uncategorized Alogliptin EXAMINE FDA FDA warning glucose control SAVOR Saxagliptin Source Type: blogs
More News: Cardiology | Diabetes | Endocrinology | Epidemiology | Heart | Heart Failure | Medical Ethics | Urology & Nephrology | Warnings